OncoSec and Dana-Farber partner on CAR-T therapies for solid tumors
California, USA-based biotech firm OncoSec Medical (Nasdaq: ONCS), a company developing intratumoral cancer immunotherapies, entered into a new collaboration with the Dana-Farber Cancer Institute to develop CAR T-cell therapies targeting solid tumors in patients with triple negative breast cancer, among other indications.
Shares of OncoSec were up 4% at $2.60 in late morning trading on Thursday following the announcement. Just a couple of months ago the company also entered into a collaboration with Duke University School of Medicine to evaluate the use of OncoSec's proprietary TAVOPLUS (enhanced interleukin (IL)-12 DNA-plasmid).
Specifically, the agreement partners OncoSec with the Marasco Laboratory, led by Dr Wayne Marasco, a world-renowned antibody engineering expert who specializes in CAR T-cell therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze